ESC 365 - Pooled safety and efficacy of inclisiran in patients with statin intolerance (ORION-10 and ORION-11)

ESC Premium Access

Pooled safety and efficacy of inclisiran in patients with statin intolerance (ORION-10 and ORION-11)

Session: Non-statin Treatment of Dyslipidemia

Topic: Drug therapy

Speaker: Professor R. Wright (Rochester, US)

Event: ESC Congress 2020

Congress Presentation

About the speaker

Professor R Scott Wright

Mayo Clinic, Rochester (United States of America)

1 presentation

0 follower

7 more presentations in this session

Updated treatment thresholds in the 2019 ESC/EAS dyslipidaemia guidelines substantially expand indications for statin use for primary prevention at population level: results from the Rotterdam Study

Speaker: Ms J. Pavlovic (Rotterdam, NL)

Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study

Speaker: Professor K. Ray (London, GB)

Non-statin lipid-lowering therapy in coronary atherosclerosis regression: A meta-analysis and meta-regression.

Speaker: Doctor L. Lobo (Buenos Aires, AR)

REDUCE-IT: total ischemic events reduced across the full range of baseline LDL cholesterol and other key subgroups

Speaker: Professor D. Bhatt (New York City, US)

REDUCE-IT: accumulation of data across prespecified interim analyses to final results

Speaker: Professor B. Olshansky (Iowa City, US)

Access the full session

Non-statin Treatment of Dyslipidemia

Speakers: Professor R. Wright, Ms J. Pavlovic, Professor K. Ray, Doctor L. Lobo, Professor D. Bhatt...

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

Related content

Open Access

Live discussion: The new ESC Heart Failure guidelines & potassium binding: What will change?

30 August 2021

ESC Premium Access

Cardiovascular benefit of lowering LDL-C below 1 mmol/L (40 mg/dl)

28 August 2021

Open Access

New recommendations for the treatment of HFrEF.

27 August 2021

ESC 365 is supported by